Takeda Pharmaceutical Co. Ltd. Takes Position in HilleVax, Inc. (NASDAQ:HLVX)

Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 6,724,000 shares of the company's stock, valued at approximately $13,919,000. HilleVax comprises 52.4% of Takeda Pharmaceutical Co. Ltd.'s portfolio, making the stock its largest position. Takeda Pharmaceutical Co. Ltd. owned approximately 13.50% of HilleVax as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Verition Fund Management LLC purchased a new position in HilleVax during the 3rd quarter valued at about $331,000. Braidwell LP purchased a new stake in HilleVax during the 3rd quarter worth approximately $1,873,000. Jane Street Group LLC boosted its position in HilleVax by 81.7% in the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after buying an additional 35,546 shares during the period. Zacks Investment Management grew its stake in shares of HilleVax by 411.9% in the third quarter. Zacks Investment Management now owns 92,803 shares of the company's stock worth $163,000 after acquiring an additional 74,673 shares in the last quarter. Finally, Barclays PLC increased its position in shares of HilleVax by 255.6% during the third quarter. Barclays PLC now owns 42,033 shares of the company's stock worth $74,000 after acquiring an additional 30,213 shares during the period. 86.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a report on Monday. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat, HilleVax currently has a consensus rating of "Hold" and a consensus target price of $3.00.

Remove Ads

HilleVax Price Performance

Shares of HilleVax stock traded down $0.10 during trading hours on Monday, hitting $1.50. The company had a trading volume of 135,817 shares, compared to its average volume of 174,976. The company's 50-day moving average is $1.82 and its two-hundred day moving average is $1.86. HilleVax, Inc. has a twelve month low of $1.47 and a twelve month high of $16.66. The company has a market cap of $74.46 million, a P/E ratio of -0.48 and a beta of 0.76.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Sell-side analysts expect that HilleVax, Inc. will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.